Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Human induced pluripotent stem cell-derived myotubes to model inclusion body myositis

  • Cantó-Santos, Judith|||0000-0002-0272-7014
  • Valls-Roca, Laura|||0000-0001-5956-6752
  • Tobías, Ester|||0000-0002-9968-3651
  • García García, Francesc Josep|||0000-0001-9021-0324
  • Guitart-Mampel, Mariona
  • Andújar-Sánchez, Félix
  • Vilaseca-Capel, Adrià
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Martín-Mur, Beatriz|||0000-0002-6006-3295
  • Padrosa, Joan
  • Peruga, Emma
  • Madrigal, Irene|||0000-0002-7229-1199
  • Segalés, Paula
  • García-Ruiz, Carmen
  • Fernández-Checa, José Carlos
  • Moreno-Lozano, Pedro J.
  • Selva O'Callaghan, Albert|||0000-0003-2823-9761
  • Sevilla, Ana|||0000-0002-9251-4759
  • Milisenda, José César|||0000-0003-0151-7872
  • Garrabou, Glòria|||0000-0001-8973-9933
Inclusion body myositis (IBM) is an inflammatory myopathy that displays proximal and distal muscle weakness. At the histopathological level, the muscles of IBM patients show inflammatory infiltrates, rimmed vacuoles and mitochondrial changes. The etiology of IBM remains unknown, and there is a lack of validated disease models, biomarkers and effective treatments. To contribute to unveil disease underpins we developed a cell model based on myotubes derived from induced pluripotent stem cells (iPSC-myotubes) from IBM patients and compared the molecular phenotype vs. age and sex-paired controls (n = 3 IBM and 4 CTL). We evaluated protein histological findings and the gene expression profile by mRNA-seq, alongside functional analysis of inflammation, degeneration and mitochondrial function. Briefly, IBM iPSC-myotubes replicated relevant muscle histopathology features of IBM, including aberrant expression of HLA, TDP-43 and COX markers. mRNA seq analysis identified 1007 differentially expressed genes (DEGs) (p-value adj < 0.01; 789 upregulated and 218 downregulated), associated with myopathy, muscle structure and developmental changes. Among these, 1 DEG was related to inflammation, 28 to autophagy and 28 to mitochondria. At the functional level, inflammation was similar between the IBM and CTL groups under basal conditions (mean cytokine expression in IBM 4.6 ± 1.4 vs. 6.7 ± 3.4 in CTL), but increased in IBM iPSC-myotubes after lipopolysaccharide treatment (72.5 ± 21.8 in IBM vs. 13.0 ± 6.7 in CTL). Additionally, autophagy was disturbed, with 40.14% reduction in autophagy mediators. Mitochondrial dysfunction was strongly manifested, showing a conserved respiratory profile and antioxidant capacity, but a 56.33% lower cytochrome c oxidase/citrate synthase ratio and a 66.59% increase in lactate secretion. Overall, these findings support patient-derived iPSC-myotubes as a relevant model for IBM, reflecting the main muscle hallmarks, including inflammation, autophagy dysfunction and mitochondrial alterations at transcriptomic, protein and functional levels.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Preclinical studies with glioblastoma brain organoid co-cultures show efficient 5-ALA photodynamic therapy

  • Pedrosa, Leire
  • Bedia, Carmen
  • Diao, Diouldé
  • Mosteiro, Alejandra
  • Ferrés, Abel
  • Stanzani, Elisabetta
  • Martínez-Soler, Fina
  • Tortosa, Avelina
  • Pineda, Estela
  • Aldecoa, Iban
  • Centellas, Marc
  • Muñoz-Tudurí, Marta
  • Sevilla, Ana
  • Sierra, Àngels
  • González Sánchez, José Juan
Background: The high recurrence of glioblastoma (GB) that occurs adjacent to the resection cavity within two years of diagnosis urges an improvement of therapies oriented to GB local control. Photodynamic therapy (PDT) has been proposed to cleanse infiltrating tumor cells from parenchyma to ameliorate short long-term progression-free survival. We examined 5-aminolevulinic acid (5-ALA)-mediated PDT effects as therapeutical treatment and determined optimal conditions for PDT efficacy without causing phototoxic injury to the normal brain tissue. Methods: We used a platform of Glioma Initiation Cells (GICs) infiltrating cerebral organoids with two different glioblastoma cells, GIC7 and PG88. We measured GICs-5-ALA uptake and PDT/5-ALA activity in dose-response curves and the efficacy of the treatment by measuring proliferative activity and apoptosis. Results: 5-ALA (50 and 100 µg/mL) was applied, and the release of protoporphyrin IX (PpIX) fluorescence measures demonstrated that the emission of PpIX increases progressively until its stabilization at 24 h. Moreover, decreased proliferation and increased apoptosis corroborated the effect of 5-ALA/PDT on cancer cells without altering normal cells. Conclusions: We provide evidence about the effectiveness of PDT to treat high proliferative GB cells in a complex in vitro system, which combines normal and cancer cells and is a useful tool to standardize new strategic therapies., This research was funded Laboratorios Gebro Pharma S.A. The authors also received support from the Spanish Ministry of Health and Consumer Affairs, the ISCIII-Subdirección General de Evaluación, AECC (Spanish Association Against Cancer. Project GCTRA16015SEDA) and the Fondo Europeo de Desarrollo Regional (FEDER) FIS-PI18/00916. A.S. was supported by the grant PGC 2018-098626-B-100 funded by MCIN/AEI/10.13039/501100011033 and by the ERDF A way of making Europe, the grant PDC 2022-133826-100 funded by MCIN/AEI/10.13039/501100011033 and by the European Union Next GenerationEU/PRTR and the Merck Salud Foundation grant RL001213. A.S. is a recipient of a Ramón y Cajal contract supported by the Grant (RYC-2016-19962) funded by MCIN/AEI/10.13039/501100011033 and by the “ESF investing in your future”. C.B. is a recipient of Grant CEX2018-000794-S funded by MCIN/AEI/10.13039/501100011033.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Preclinical studies with glioblastoma brain organoid co-cultures show efficient 5-ALA photodynamic therapy

  • Pedrosa, Leire
  • Bedia, Carmen
  • Diao, Diouldé
  • Mosteiro, Alejandra
  • Ferrés, Abel
  • Stanzani, Elisabetta
  • Martínez-Soler, Fina
  • Tortosa, Avelina
  • Pineda, Estela
  • Aldecoa, Iban
  • Centellas, Marc
  • Muñoz-Tudurí, Marta
  • Sevilla, Ana
  • Sierra, Àngels
  • González Sánchez, José Juan
Background: The high recurrence of glioblastoma (GB) that occurs adjacent to the resection cavity within two years of diagnosis urges an improvement of therapies oriented to GB local control. Photodynamic therapy (PDT) has been proposed to cleanse infiltrating tumor cells from parenchyma to ameliorate short long-term progression-free survival. We examined 5-aminolevulinic acid (5-ALA)-mediated PDT effects as therapeutical treatment and determined optimal conditions for PDT efficacy without causing phototoxic injury to the normal brain tissue. Methods: We used a platform of Glioma Initiation Cells (GICs) infiltrating cerebral organoids with two different glioblastoma cells, GIC7 and PG88. We measured GICs-5-ALA uptake and PDT/5-ALA activity in dose-response curves and the efficacy of the treatment by measuring proliferative activity and apoptosis. Results: 5-ALA (50 and 100 µg/mL) was applied, and the release of protoporphyrin IX (PpIX) fluorescence measures demonstrated that the emission of PpIX increases progressively until its stabilization at 24 h. Moreover, decreased proliferation and increased apoptosis corroborated the effect of 5-ALA/PDT on cancer cells without altering normal cells. Conclusions: We provide evidence about the effectiveness of PDT to treat high proliferative GB cells in a complex in vitro system, which combines normal and cancer cells and is a useful tool to standardize new strategic therapies., This research was funded Laboratorios Gebro Pharma S.A. The authors also received support from the Spanish Ministry of Health and Consumer Affairs, the ISCIII-Subdirección General de Evaluación, AECC (Spanish Association Against Cancer. Project GCTRA16015SEDA) and the Fondo Europeo de Desarrollo Regional (FEDER) FIS-PI18/00916. A.S. was supported by the grant PGC 2018-098626-B-100 funded by MCIN/AEI/10.13039/501100011033 and by the ERDF A way of making Europe, the grant PDC 2022-133826-100 funded by MCIN/AEI/10.13039/501100011033 and by the European Union Next GenerationEU/PRTR and the Merck Salud Foundation grant RL001213. A.S. is a recipient of a Ramón y Cajal contract supported by the Grant (RYC-2016-19962) funded by MCIN/AEI/10.13039/501100011033 and by the “ESF investing in your future”. C.B. is a recipient of Grant CEX2018-000794-S funded by MCIN/AEI/10.13039/501100011033.